Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

Furthermore, Eli Lilly's weight-loss medication Zepbound has become the first to be FDA-approved for sleep apnea, offering ...

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.

Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...